Abstract
BackgroundTNFi drug survival is one of the valid outcome measure in rheumatological diseases. Patients with psoriatic arthritis (PsA) usually have both joint/back pain diseases and skin disorders. Thus, efficacy of...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have